Sign up USA
Proactive Investors - Run By Investors For Investors

AusCann Group Holdings welcomes regulatory change

The change enables terminally ill patients to access medicinal cannabis.
AusCann Group Holdings welcomes regulatory change
Shares are over 70% above their February listing price

AusCann Group Holdings (ASX:AC8) welcomes changes that increase the ability of Australian medical practitioners to prescribe cannabinoid medicines to critically ill patients.

The Therapeutic Goods Administration (TGA) currently has two access pathways in which Australian medical practitioners may prescribe unregistered cannabinoid medicines.

A recent disallowance motion by Senator Di Natale changes the regulations to enable terminally ill patients to access medicinal cannabis products.

Elaine Darby, managing director, commented: “AusCann believes that excluding cannabinoid medicines from this pathway was not necessary given the safety evidence in respect to cannabinoids that has come out of pre-clinical and clinical studies.

“We are pleased terminally ill patients will now be able to access cannabinoid medicines through the TGA’s Special Access Scheme Category A.”


The changes explained

The TGA’s two access pathways in which Australian medical practitioners may prescribe unregistered cannabinoid medicines are the Authorised Prescriber Scheme (APS) and the Special Access Scheme (SAS) Category B.

Both of these pathways require the medicinal practitioner to apply for and wait for approval from the TGA prior to being able to prescribe.

SAS Category A does not require prior approval but is a process where the medical practitioner notifies the TGA they have prescribed the medicines.

Prior to the changes, any unregistered therapeutic goods can potentially be supplied via the
SAS Category A process, except for:

- Prohibited substances in Schedule 9 of the Poisons Standard; and
- Medicinal cannabis products.

Senator Di Natale’s disallowance motion changes the regulation to enable terminally ill patients to access medicinal cannabis products through the TGA SAS Category A process.


Background

AusCann is a medical cannabis company that commenced trading on the ASX in February after it raised the maximum $5 million under a prospectus offering.

The company aims to produce and provide high quality, affordable and clinically validated cannabis medicines to patients.

It is bringing together leading expertise and operations across all aspects of the medical cannabis value chain, from cultivation and production, through to manufacture and distribution of products and has built a strong team of experts and partners across the globe.

Partners include:

- Canopy Growth Corp (CVE:CGC): the largest producer of medicinal cannabis globally;
- DayaCann: the only licensed medicinal cannabis grower in Chile; and
- Tasmanian Alkaloids: producer of ~40% of the world’s alkaloid raw material.

During early May, AusCann was granted a licence to cultivate medicinal cannabis in Australia.

The global cannabis market is currently valued at US$50 billion and growing, with an estimated 600,000 patients currently receiving treatment.

View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

woman at a microscope
September 04 2017
Lead product Lojuxta generated revenues of €5.75mln in the first-half
researcher using microscope
September 28 2017
A total of £6mln is expected to come via a share placing and up to a further £2mln through an open offer of stock to existing investors

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use